Prometheus Financial Statements From 2010 to 2024

RXDXDelisted Stock  USD 199.92  0.24  0.12%   
Prometheus Biosciences financial statements provide useful quarterly and yearly information to potential Prometheus Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Prometheus Biosciences financial statements helps investors assess Prometheus Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Prometheus Biosciences' valuation are summarized below:
Prometheus Biosciences does not presently have any trending fundamental ratios for analysis.
Check Prometheus Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Prometheus Biosciences' main balance sheet or income statement drivers, such as , as well as many indicators such as . Prometheus financial statements analysis is a perfect complement when working with Prometheus Biosciences Valuation or Volatility modules.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Prometheus Biosciences Company Return On Equity Analysis

Prometheus Biosciences' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Prometheus Biosciences Return On Equity

    
  -0.33  
Most of Prometheus Biosciences' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prometheus Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Prometheus Biosciences has a Return On Equity of -0.333. This is 98.61% lower than that of the Biotechnology sector and 99.09% lower than that of the Health Care industry. The return on equity for all United States stocks is 7.42% higher than that of the company.

Prometheus Biosciences Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Prometheus Biosciences's current stock value. Our valuation model uses many indicators to compare Prometheus Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Prometheus Biosciences competition to find correlations between indicators driving Prometheus Biosciences's intrinsic value. More Info.
Prometheus Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Prometheus Biosciences' earnings, one of the primary drivers of an investment's value.

About Prometheus Biosciences Financial Statements

Prometheus Biosciences investors use historical fundamental indicators, such as Prometheus Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Prometheus Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases . Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. Prometheus Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Consideration for investing in Prometheus Stock

If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets